Central European Journal of Medicine

, Volume 6, Issue 2, pp 158–162 | Cite as

Serum IGF-1 and IGFBP-3 levels in subclinical hypothyroid women

  • Huriye Balci
  • Tijen Yesim Erdem
  • Serdal Ugurlu
  • Demet Ozgul Yetkin
  • I. Murat Bolayirli
  • Munire Hacibekiroglu
  • Ertugrul Tasan
Research Article
  • 79 Downloads

Abstract

Thyroid status is known to influence growth in mammals. The aim of this study is to investigate the possible relationship between autoimmune subclinical hypothyroidism and growth hormone (GH), insulin-like growth factor-1(IGF-1) and insulin-like growth factor binding protein-3(IGFBP-3) levels. Thirty-five women with autoimmune subclinical hypothyroidism, 33 years of age, were used as controls and enrolled in the study. Free triiodothyronin (FT3), free thyroxin(FT4), thyrotropin(TSH), anti-thyroid peroxidase(Anti-TPO), anti-thyroglobuline(Anti-Tg), GH, IGF-1 and IGFBP-3 levels were measured in blood samples and correlations among these parameters were evaluated. We found no significant differences in GH, IGF-1 or IGFBP-3 between patients and controls. In patients and controls, there were no correlations among thyroid hormones and IGF-1 or IGFBP-3 levels, but GH levels were correlated with FT3, FT4 and TSH only in patients’ group. In controls, only IGF-1 and IGFBP-3 levels were correlated. The present study suggests that subclinical hypothyroidism with high TSH and antibody status does not affect IGF-1 and IGFBP-3 levels in adult women. To our knowledge, this is the first study concerning the relationship between autoimmune subclinical hypothyroidism and IGF-1 and IGFBP-3 levels.

Keywords

IGF-1 IGFBP-3 Autoimmune subclinical hypothyroidism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Fernandez M, Pirondi S, Manservigi M, Giardino L, Calzà L. Thyroid hormone participates in the regulation of neural stem cells and oligodendrocyte precursor cells in the central nervous system of adult rat. Eur J Neurosci. 2004 Oct;20(8):2059–2070CrossRefPubMedGoogle Scholar
  2. [2]
    Yoshida K, Aiyama S, Uchida M, Kurabuchi S. Role of thyroid hormone in the initiation of EGF (epidermal growth factor) expression in the sublingual gland of the postnatal mouse. Anat Rec A Discov Mol Cell Evol Biol. 2005 Jun;284(2):585–593PubMedGoogle Scholar
  3. [3]
    Dainiak N, Sutter D, Kreczko S. L-triiodothyronine augments erythropoietic growth factor release from peripheral blood and bone marrow leukocytes. Blood. 1986 Dec;68(6):1289–1297PubMedGoogle Scholar
  4. [4]
    Miell JP, Zini M, Quin JD, Jones J, Portioli I, Valcavi R. Reversible effects of cessation and recommencement of thyroxine treatment on insulinlike growth factors (IGFs) and IGF-binding proteins in patients with total thyroidectomy. J Clin Endocrinol Metab. 1994; 79:1507–1512CrossRefPubMedGoogle Scholar
  5. [5]
    Angervo M, Toivonen J, Leinonen P, Välimäki M, Seppälä M. Thyroxine withdrawal is accompanied by decreased circulating levels of insulin-like growth factor binding protein-1 in thyroidectomized patients. J Clin Endocrinol Metab. 1993; 76:1199–1201CrossRefPubMedGoogle Scholar
  6. [6]
    Näntö-Salonen K, Muller HL, Hoffman AR, Vu TH, Rosenfeld RG. Mechanisms of thyroid hormone action on the insulin-like growth factor system: all thyroid hormone effects are not growth hormone mediated. Endocrinology. 1993; 132:781–788CrossRefPubMedGoogle Scholar
  7. [7]
    Ozon A, Alikaşifoǧlu A, Yordam N. Influence of iodine supplementation on serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) levels in severe iodine deficiency. Turk J Pediatr. 2004; 46:303–308PubMedGoogle Scholar
  8. [8]
    Shintani N, Nohira T, Hikosaka A, Kawahara A. Tissue-specific regulation of type III iodothyronine 5-deiodinase gene expression mediates the effects of prolactin and growth hormone in Xenopus metamorphosis. Dev Growth Differ. 2002 Aug;44(4):327–335CrossRefPubMedGoogle Scholar
  9. [9]
    Laurberg P, Jakobsen PE, Hoeck HC, Vestergaard P. Growth hormone and thyroid function: is secondary thyroid failure underdiagnosed in growth hormone deficient patients? Thyroidology. 1994 Dec;6(3):73–79PubMedGoogle Scholar
  10. [10]
    Iglesias P, Bayón C, Méndez J, Gancedo PG, Grande C, Diez JJ. Serum insulin-like growth factor type 1, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3 concentrations in patients with thyroid dysfunction. Thyroid. 2001; 11:1043–1048CrossRefPubMedGoogle Scholar
  11. [11]
    Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab. 1993; 76:950–955CrossRefPubMedGoogle Scholar
  12. [12]
    O’shea PJ, Bassett JH, Sriskantharajah S, Ying H, Cheng SY, Williams GR. Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor alpha1 or beta. Mol Endocrinol. 2005 Dec;19(12):3045–3059CrossRefPubMedGoogle Scholar
  13. [13]
    Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988; 66:1158–1165CrossRefPubMedGoogle Scholar
  14. [14]
    Eggo MC, King WJ, Black EG, Sheppard MC. Functional human thyroid cells and their insulinlike growth factor-binding proteins: regulation by thyrotropin, cyclic 3′,5′ adenosine monophosphate, and growth factors. J Clin Endocrinol Metab. 1996; 81:3056–3062CrossRefPubMedGoogle Scholar
  15. [15]
    Nielsen CH, Brix TH, Leslie RG, Hegedüs L. A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a selfantigen, thyroid peroxidase. Clin Immunol. 2009 Nov;133(2):218–227CrossRefPubMedGoogle Scholar
  16. [16]
    Miell JP, Zini M, Quin JD, Jones J, Portioli I, Valcavi R. Reversible effects of cessation and recommencement of thyroxine treatment oninsulinlike growth factors (IGFs) and IGF-binding proteins in patients withtotal thyroidectomy. J Clin Endocrinol Metab. 1994; 79:1507–1512CrossRefPubMedGoogle Scholar
  17. [17]
    Kandemir N, Yordam N, Oguz H. Age-related differences in serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels in congenital hypothyroidism. J Pediatr Endocrinol Metab. 1997; 10: 379–385PubMedGoogle Scholar
  18. [18]
    Bona G, Rapa A, Boccardo G, Silvestro L, Chiorboli E. IGF-1 and IGFBP in congenital and acquired hypothyroidism after long-term replacement treatment. Minerva Endocrinol. 1999; 24:51–55PubMedGoogle Scholar
  19. [19]
    Aydin K, Bideci A, Kendirci M, Cinaz P, Kurtoglu S. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels of children living in an iodine- and selenium-deficient endemic goiter area. Biol Trace Elem Res. 2002; 90: 25–30CrossRefPubMedGoogle Scholar
  20. [20]
    Alikaşifoǧlu A, Ozön A, Yordam N. Serum insulinlike growth factor-I (IGF-I) and IGF-binding protein-3 levels in severe iodine deficiency. Turk J Pediatr. 2002; 44:215–218PubMedGoogle Scholar
  21. [21]
    Näntö-Salonen K, Rosenfeld RG. Insulin-like growth factor binding protein expression in the hypothyroid rat is age dependent. Endocrinology. 1992; 131:1489–1496CrossRefPubMedGoogle Scholar
  22. [22]
    Ramos S, Goya L, Alvarez C, Martín MA, Pascual-Leone AM. Effect of thyroxine administration on the IGF/IGF binding protein system in neonatal and adult thyroidectomized rats. J Endocrinol. 2001; 169:111–122CrossRefPubMedGoogle Scholar
  23. [23]
    Ikeda T, Fujiyama K, Takeuchi T, Honda M, Mokuda O, Tominaga M, Mashiba H. Effect of thyroid hormone on somatomedin C release from perfused rat liver. Experientia. 45:170–180Google Scholar
  24. [24]
    Cassio A, Cacciari E, Balsamo A, Colli C, Pasini A, Salvioli GP, Lanari M, de Iasio R, Boschi S, Pirazzoli P. Low growth hormone-binding protein in infants with congenital hypothyroidism. J Clin Endocrinol Metab. 1998; 83: 3643–3646CrossRefPubMedGoogle Scholar
  25. [25]
    Akin F, Yaylali GF, Turgut S, Kaptanoglu B. Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction. Growth Horm IGF Res. 2009 Jun;19(3):252–255CrossRefPubMedGoogle Scholar
  26. [26]
    Inukai T, Takanashi K, Takebayashi K, Fujiwara Y, Tayama K, Takemura Y. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases. Horm Metab Res 1999; 31: 576–579CrossRefPubMedGoogle Scholar
  27. [27]
    Del Monte P, Bernasconi D, De Conca V, Randazzo M, Meozzi M, Badaracco B, Mesiti S, Marugo M. Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C. Horm Res. 1995;44(3):105–109CrossRefPubMedGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Huriye Balci
    • 1
  • Tijen Yesim Erdem
    • 2
  • Serdal Ugurlu
    • 3
  • Demet Ozgul Yetkin
    • 4
  • I. Murat Bolayirli
    • 1
  • Munire Hacibekiroglu
    • 1
  • Ertugrul Tasan
    • 5
  1. 1.Fikret Biyal Central Research Laboratory, Cerrahpasa Medical FacultyIstanbul UniversityIstanbulTurkey
  2. 2.Division of Endocrinology-Metabolism and Diabetes and Department of MedicineHaseki Education and Research HospitalIstanbulTurkey
  3. 3.Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical FacultyIstanbul UniversityIstanbulTurkey
  4. 4.Division of Endocrinology-Metabolism and Diabetes and Department of MedicineGoztepe Education and Research HospitalIstanbulTurkey
  5. 5.Division of Endocrinology-Metabolism and Diabetes and Department of Medicine, Cerrahpasa Medical FacultyIstanbul UniversityIstanbulTurkey

Personalised recommendations